Patents are legal documents drawn up by inventors and lawyers and granted by various patent offices around the world, to protect the inventors' intellectual property. The short description accompanying each patent in this Patents section is therefore taken from the legal document as is, with minor corrections for Greek symbols and obvious spelling errors. The patents included in this section may be for material products (defensins or defensin-like peptides or nucleic acid sequences, synthetic or natural) or for novel methods of detecting, quantitating, synthesizing, or delivering antimicrobial peptides/nucleic acid sequences in general. The curators' criterion for inclusion in this section is broader for novel methods than for material products, in the hope that these methods may in future be similarly applied to defensins.

Patents in which the defensins or defensin-like material products and methods as above are not novel, such as biomarker sets containing unmodified defensin or defensin-like peptides or oligonucleotides, are excluded from this section. The exception to such exclusions is where the patent provides other novel defensin-related material products or methods in addition to those non-novel of the biomarker set itself. This exclusion is because the reasonable presence of defensin or defensin-like sequences or indeed any other sequences in patented biomarker sets is necessarily attributed to some prior discovery of disease state correlation with such sequences. The curators have observed therefore that the novel discovery in biomarker-related patents is often the method of biomarker array analysis and validation as well as its resultant implications for diagnostics and prognostics. The expert evaluation of such biomarker analysis and validation is well outside the scope of the Defensins Knowledgebase. The reader is respectfully referred to a biomarker database specific to the disease to perform his own assessment of the validity of the biomarker.

Methods not pertaining to the antimicrobial activity of defensins, but where defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences are suggested in some unambiguous detail to play a useful role in the method, with or without supporting experimental evidence, are included as well in this section. Patents in which natural defensins are up/downregulated in a clearly defined signal transduction pathway as a result of the unrelated patented novel compound or method are also included. And lastly, all patents showing experimental work done with defensins or antimicrobial peptides or small cationic peptides or disulphide-bonded peptides or their respective nucleic acid sequences, where such peptides or nucleic acid sequences are not the experimental controls, are included without exception.

The data in this section have been extracted from the academic version of SciFinder Scholar 2007 and from public Google search - a wide range of defensin-related patents are included.


Results 91 - 100 of 333

<< Previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | Next >>

Last updated: 20th February 2008

Patent No.: WO 092332
SARS virus polypeptides and antibodies for diagnosis and treatment of SARS and related viral infection.
Applicant: Lomas L, Pak B, Fu S, Tornatore P, Viner R, Weinberger SR, Yip T-T (2004)
The present invention provides, inter alia, SARS-related polypeptides, i.e., polypeptides assocd. with Severe Acute Respiratory Syndrome (SARS). The present invention also provides antibodies that specifically bind SARS-related polypeptides. In addn., the present invention provides methods for detecting viral infection assocd. with SARS by detecting decreased levels of defensin such as alpha-defensin 1-3.

Patent No.: WO 074807
Methods of screening for inhibitors of Streptococcus pyogenes extracellular protein SIC, for treatment of infections.
Applicant: Akesson P, Bjoerck L, Sjoeholm A (2004)
An assay method for an anti-bacterial agent comprising: (a) providing as a first component protein SIC; (b) providing as a second component an antibacterial peptide; (c) contacting the first component with a test substance in the presence of the second component; and (d) determining the interaction or activity of the first component with the second component to determine thereby whether a test substance is an effective anti-bacterial agent. In a particular embodiment, the antibacterial peptides are alpha-defensin or LL-37.

Patent No.: WO 072239
Genes for defensin sequence homologs from plants for use in engineering plant resistance to phytopathogenic fungi.
Applicant: Wu G, Lageweg W, Stuiver MH, Liu L, Wei W, Dojka M. (2004)
Plant genes for homologs of defensins that have antifungal activity are identified for use in the improvement of plant resistance to phytopathogenic fungi. These proteins and the corresponding genes may also be used to improve animal resistance to zoopathogenic fungi (no data.). The antifungal activity of some of these proteins is demonstrated against Fusarium graminearum, Septoria tritici, and Mycosphaerella fijiensis. Peptides were also effective when applied to infected wheat.

Patent No.: WO 063219
Sequence homologs of defensins from human and cDNAs encoding them and their diagnostic and therapeutic uses.
Applicant: Fagan RJ, Michalovich D, White SJ, Power C, Yorke M (2004)
This invention relates to two novel human proteins, termed INSP108 and INSP109, identified by sequence homology as members of the defensin family of proteins and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention, and treatment of disease. Cloning of cDNA templates and by exon assembly from genomic DNA is described, as are various assays for detection of putative activities.

Patent No.: WO 056307
Disease treatment via antimicrobial peptide inhibitors.
Applicant: Hillman Y (2004)
A method of treating a disease in a subject in need thereof is disclosed. The method comprises providing to the subject a therapeutically effective amt. of a compd. being capable of decreasing an activity and/or level of an antimicrobial peptide (AMP) and/or AMP-like mol., thereby treating the disease in the subject in need thereof. Significant inhibition of growth of malignant human keratinocytes was induced by 1.0 microg/mL of anti-human beta-defensin-2 antibody. The antibody treatment was also obsd. to result in significantly enhanced substrate attachment of the cells.

Patent No.: WO 055041
Defensin-inducing peptides from Fusobacterium nucleatum with uses in the treatment of bacterial infections.
Applicant: Weinberg A (2004)
Novel peptides from Fusobacterium nucleatum that can induce the synthesis of defensins are described for use in the treatment of bacterial infection. Purifn. of the proteins from F. nucleatum cell walls is described.

Patent No.: WO 054603
Use of beta defensin or its inducing agents for treating HIV-1 associated with chemokine receptor CXCR4.
Applicant: Weinberg A (2004)
The present invention provides use of beta defensin isoform 2 or 3 or its inducing agents for treating HIV-1 assocd. with chemokine receptor CXCR4. In a preferred embodiment, FAD-I proteins are beta defensin inducing agents.

Patent No.: WO 054366
Antifungal screening tool.
Applicant: Cammue B, Thevissen K, Francois I, Leipelt M, Heinz E, Warnecke D, Ferket K (2004)
The invention demonstrates that the antifungal activity of given plant and insect defensins is mediated via the interaction of the defensins with fungal membrane lipids, said lipids being selected from the group comprising steryl glucosides and sphingolipids, more particularly the glycosphingolipid mannose-(inositol-phosphate)2-ceramide (M(IP)2C) and the glucosylceramides. Based on these findings a method is provided for assessing the antifungal properties of a compd. characterized in that the method evaluates the interaction of a compd. with the steryl glucosides and sphingolipids in or derived from the fungal cell membrane.

Patent No.: WO 053057
Reporter gene systems to screen for effectors of Toll-like receptors.
Applicant: Gupta SK, Ghosh TK, Fink JR (2004)
Reporter gene systems that can be used to screen for modulators of Toll-like receptors are described. These systems include an expression cassette for the Toll-like receptor gene and a second cassette for a reporter gene under control of the Toll-like receptor, e.g. from a gene for a cytokine, chemokine, a co-stimulatory mol. or a defensin. The method may be used to screen for effectors that do not activate an NF-kappaB-dependent pathway. The system uses an animal cell line, preferably a Namalwa cell, as expression host.

Patent No.: WO 038002
Vaccine vectors encoding TLR ligand or defensin domain, antigen domain, and antibody domain for modulating dendritic cell and treating cancer, allergy, autoimmune disease, infection and inflammation.
Applicant: Biragyn A, Kwak LW (2004)
Methods are provided to reduce inflammation and to treat abnormal physiol. conditions or diseases by modulating a robust, type 1 adaptive immune response in vivo. The present invention also provides proteins and the nucleotides encoding them, compns., vectors (including vaccine vectors) and delivery vehicles, cells capable of expressing the proteins, and kits for practicing the invention. The proteins and nucleotides encode a chimeric protein having mol. wt. of 100 kDa comprising (1) a TLR ligand domain contg. a defensin domain, and (2) an antigen domain or an antibody domain. The antigen domain is from a self antigen, tumor antigen, microorganism antigen, etc. The chimeric proteins or vaccine vectors are useful as adjuvant for augmenting cellular or humoral immune response against cancer, allergy, asthma, autoimmune disease, infection and inflammation.